Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 1
1982 2
1983 3
1984 2
1985 5
1986 1
1987 1
1988 4
1989 8
1990 6
1991 7
1992 7
1993 3
1994 12
1995 13
1996 13
1997 13
1998 12
1999 13
2000 16
2001 9
2002 24
2003 28
2004 36
2005 34
2006 37
2007 41
2008 48
2009 47
2010 48
2011 50
2012 56
2013 71
2014 64
2015 54
2016 67
2017 53
2018 53
2019 51
2020 59
2021 52
2022 49
2023 52
2024 38
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,137 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.
Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Kumar P, et al. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):75-89. doi: 10.1093/gerona/glac135. J Gerontol A Biol Sci Med Sci. 2023. PMID: 35975308 Free PMC article. Clinical Trial.
In prior studies, we identified that deficiency of the intracellular antioxidant glutathione (GSH) could play a role and reported that supplementing GlyNAC (combination of glycine and N-acetylcysteine [NAC]) in aged mice improved GSH deficiency, OxS, mitochondrial fatty-ac …
In prior studies, we identified that deficiency of the intracellular antioxidant glutathione (GSH) could play a role and reported that suppl …
Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials.
Lee TM, Lee KM, Lee CY, Lee HC, Tam KW, Loh EW. Lee TM, et al. Aust N Z J Psychiatry. 2021 Feb;55(2):196-206. doi: 10.1177/0004867420952540. Epub 2020 Sep 8. Aust N Z J Psychiatry. 2021. PMID: 32900213
Here, we analyzed the treatment effects of N-acetylcysteine on autism spectrum disorder in randomized controlled trials. STUDY DESIGN: Updated systematic review and meta-analysis. ...DATA SYNTHESIS: After 8-12 weeks of N-acetylcysteine supplementation, the pooled re …
Here, we analyzed the treatment effects of N-acetylcysteine on autism spectrum disorder in randomized controlled trials. STUDY DESIGN …
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20. N Engl J Med. 2012. PMID: 22607134 Free PMC article. Clinical Trial.
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. ...
BACKGROUND: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic …
N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. Grant JE, et al. JAMA Psychiatry. 2016 May 1;73(5):490-6. doi: 10.1001/jamapsychiatry.2016.0060. JAMA Psychiatry. 2016. PMID: 27007062 Clinical Trial.
RESULTS: Of the 66 participants (31 randomized to placebo and 35 to N-acetylcysteine) included in the analysis, 59 (89%) were women; mean (SD) age was 34.8 (11.0) years. ...At the study's end point, of the 53 participants who completed the study, 15 of the 32 participants …
RESULTS: Of the 66 participants (31 randomized to placebo and 35 to N-acetylcysteine) included in the analysis, 59 (89%) were women; …
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free PMC article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC treatment may be effective in …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obst …
Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study.
Nabi T, Nabi S, Rafiq N, Shah A. Nabi T, et al. Saudi J Gastroenterol. 2017 May-Jun;23(3):169-175. doi: 10.4103/1319-3767.207711. Saudi J Gastroenterol. 2017. PMID: 28611340 Free PMC article. Clinical Trial.
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and little is known about the use of N-acetylcysteine (NAC) in NAI-ALF. A randomized case control study was conducted with the aim to de …
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and …
N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure.
Siu JT, Nguyen T, Turgeon RD. Siu JT, et al. Cochrane Database Syst Rev. 2020 Dec 9;12(12):CD012123. doi: 10.1002/14651858.CD012123.pub2. Cochrane Database Syst Rev. 2020. PMID: 33294991 Free PMC article.
OBJECTIVES: To assess the benefits and harms of N-acetylcysteine compared with placebo or no N-acetylcysteine, as an adjunct to usual care, in people with non-paracetamol-related acute liver failure. ...For all-cause mortality at 21 days between adults receiving N- …
OBJECTIVES: To assess the benefits and harms of N-acetylcysteine compared with placebo or no N-acetylcysteine, as an adjunct t …
N-acetylcysteine as a treatment for substance use cravings: A meta-analysis.
Winterlind EL, Malone SG, Setzer MR, Murphy MA, Saunders D, Gray JC. Winterlind EL, et al. Addict Biol. 2024 Nov;29(11):e70001. doi: 10.1111/adb.70001. Addict Biol. 2024. PMID: 39556483 Free PMC article.
N-acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and substance craving in individuals with substance use disorders (SUDs), possibly through its potential to regulate glutamate. ...
N-acetylcysteine (NAC) may serve as a novel pharmacotherapy for substance use and substance craving in individuals with substance use …
N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A, Alfano F, Bigoni T, Mancini L, Mawass A, Baraldi F, Aljama C, Contoli M, Miravitlles M. Papi A, et al. Arch Bronconeumol. 2024 May;60(5):269-278. doi: 10.1016/j.arbres.2024.03.010. Epub 2024 Mar 18. Arch Bronconeumol. 2024. PMID: 38555190 Free article. English, Spanish.
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic mechanism in chronic respiratory conditions such as COPD and chronic bronchitis (CB). ...
INTRODUCTION: N-acetylcysteine (NAC) is a mucolytic agent with antioxidant properties. Oxidative stress is a key pathogenic mechanism …
1,137 results